Pharmafile Logo

New agency

Harriet Karia

Cuttsy+Cuttsy appoints Harriet Karia as Managing Director

Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.

Cuttsy + Cuttsy

- PMLiVE

Novartis and Voyager enter gene therapy partnership worth over $1.2bn

The companies will advance candidates for Huntington’s disease and spinal muscular atrophy

- PMLiVE

AstraZeneca and Ionis’ Wainua granted FDA approval for rare disease ATTRv-PN

ATTRv-PN leads to peripheral nerve damage with motor disability within five years of diagnosis

- PMLiVE

MIT researchers identify new class of antibiotic candidates using AI

MRSA is a drug-resistant bacterium responsible for 10,000 deaths a year in the US

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

Approximately 17,000 cases of melanoma are diagnosed in the UK every year

- PMLiVE

ICR study predicts response to radium-233 treatment in prostate cancer bone metastases

The findings could help determine which patients would benefit from the treatment

- PMLiVE

Breaking barriers: strategies for expanding patient access to cell and gene therapies

How innovation can help to overcome the hurdles that prevent access to cell and gene therapies

- PMLiVE

AstraZeneca to acquire cell therapy specialist Gracell in deal worth up to $1.2bn

The transaction includes a clinical-stage candidate being evaluated as a treatment for multiple myeloma

- PMLiVE

World Health Organization adds second malaria vaccine to prequalification list

The addition is expected to result in sufficient malaria vaccine supply for children

- PMLiVE

T is for trouble

Evolution trumps transformation

- PMLiVE

GSK gains rights to Hansoh’s ADC candidate in deal worth more than $1.7bn

HS-20093 is being developed for a range of solid tumour types, including lung cancer

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links